The study, published in Nature Biomedical Engineering, focused on addressing why prostate cancer is often considered an “immune-cold” tumor. Unlike cancers that attract large numbers of immune cells, prostate tumors typically contain very few T cells, limiting the impact of immunotherapies designed to stimulate immune responses against cancer.

Making Tumors Visible to the Immune System

Investigators developed an RNA-targeting CRISPR-Cas13 approach that alters the behavior of cancer cells without cutting their DNA. In mouse models, the technology increased immune cell infiltration into tumors and improved responses to checkpoint inhibitor therapy, leading to more effective tumor destruction.

According to the research team, the platform could eventually be used alongside existing immunotherapies to improve outcomes not only in prostate cancer but also in other tumor types that are poorly recognized by the immune system.

The Role of Shortened mRNA in Cancer

The work builds on earlier discoveries showing that many cancer cells produce abnormally shortened messenger RNA (mRNA) molecules. mRNA serves as the intermediary between DNA and protein production, carrying genetic instructions to cellular machinery.

These shortened transcripts are often more stable and can persist longer within cells, enabling sustained production of proteins that support tumor growth, adaptation, and treatment resistance. Previous research has shown that this phenomenon occurs across a wide range of cancers.

How Prostate Tumors Evade Immune Detection

The researchers identified a molecular pathway that helps prostate tumors escape immune surveillance.

Central to this process is a protein called SPSB1, which promotes the breakdown of the major histocompatibility complex class I (MHC-I), a key structure that allows T cells to recognize abnormal cells. In prostate cancer, the mRNA responsible for producing SPSB1 becomes abnormally shortened, leading to increased protein production.

Elevated SPSB1 levels reduce the presence of MHC-I on tumor cells. As a result, cancer cells become less visible to the immune system, making checkpoint inhibitor therapies far less effective.

Restoring an Immune “Beacon”

To reverse this effect, scientists engineered a CRISPR-Cas13 system designed to prevent shortening of the SPSB1 mRNA molecule. Rather than cutting RNA, the tool binds to a specific region and blocks the cellular machinery responsible for truncating the molecule.

Maintaining the mRNA in its full-length form reduced SPSB1 production, which in turn allowed MHC-I levels to recover. The restored MHC-I signaling improved the ability of T cells to locate and attack cancer cells.

When combined with immune checkpoint therapy, the RNA-editing approach produced substantially stronger anti-tumor responses in prostate cancer models than immunotherapy alone.

Early Promise With Minimal Off-Target Effects

Researchers reported no detectable off-target activity during their preclinical analyses, an encouraging finding for a technology intended to precisely modify RNA behavior. The results also provide proof of concept that cancer-associated mRNA shortening can be reversed therapeutically.

While the strategy remains in the experimental stage and has not yet been tested in humans, the findings suggest that manipulating RNA processing could represent a new avenue for sensitizing immune-resistant cancers to treatment.

Looking Ahead

The study highlights a potentially transformative approach to cancer therapy: combining immunotherapy with targeted RNA engineering. By restoring molecular signals that help immune cells recognize tumors, the CRISPR-based platform may help convert immune-cold cancers into tumors that are more susceptible to immune attack.

Further research will be required to establish safety and effectiveness in human studies, but the findings offer an encouraging step toward expanding the benefits of immunotherapy to patients with prostate cancer and other difficult-to-treat malignancies.